Cognitive improvements in early stages
The stage three trial of AR1001 shows it slows cognitive decline in patients with early Alzheimer’s disease by 31%. This study, involving 604 people across 13 countries including the UK, was presented at the Clinical Trials on Alzheimer’s Disease conference in Boston. The medication, produced by South Korean company AriBio, is a phosphodiesterase-5 inhibitor from the same family of medicines as Viagra. I see the 31% reduction in decline among patients not receiving any other treatment as the most significant finding. This once-a-day oral tablet takes a different approach to existing treatments because it relaxes blood vessels to increase blood flow to the brain rather than targeting amyloid. This medication acts on a specific enzyme and influences several other processes involved in brain function. Prof Tara Spires-Jones of the University of Edinburgh says the drug acts through boosting blood flow and likely also directly stimulating pathways in brain cells that promote learning and memory.
Challenges with multi-drug users
The drug clearly works for some, though it did not achieve statistically significant results in the wider group of patients taking other drugs for Alzheimer’s. Dr Sheona Scales, director of research at Alzheimer’s Research UK, says the findings are "very encouraging" and mark "an important milestone in the search for new Alzheimer’s treatments" because the oral drug takes a different approach. However, the benefit was not significant for those taking other commonly used Alzheimer’s medications alongside the trial drug. Dr Richard Oakley, associate director of research and innovation at Alzheimer’s Society, notes that the drug effectively slowed decline in memory and thinking for some, but it was not as effective for people taking other drugs for Alzheimer’s symptoms. Dr Oakley says these results are an exciting sign that doctors could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms. I find the lack of efficacy in the combined group a major problem that requires further investigation. The side-effects reported over the year-long trial were mostly mild to moderate. Dr Oakley adds that people should not take Viagra to try to treat Alzheimer’s, as the drug is being developed specifically for Alzheimer’s disease. Because Alzheimer’s is forecast to affect 153 million people worldwide by 2050 and currently has no cure, this novel approach is interesting, but regulatory bodies must still scrutinize the results before doctors prescribe it.
